AST/SGOT and ALT/SGPT ? . X ULN
COHORT : AST (SGOT) and ALT (SGPT) =<  X ULN within  days of treatment initiation
AST(SGOT)/ALT(SGPT) ? . X institutional ULN
AST (SGOT) and ALT (SGPT) ? . x ULN.
RANDOMIZED PHASE II CLINICAL TRIAL: Within  days of registration: AST (SGOT) and ALT (SGPT) =< . X ULN OR =<  X ULN for subjects with liver metastases
AST/ALT (SGOT/SGPT) <  ULN
Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) ? . x upper limit of normal (ULN). In the case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be ? . x ULN.
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: AST (SGOT)/ALT (SGPT) =< . X ULN if hepatic metastases are present
EXPANDED ACCESS COHORT: AST(SGOT)/ALT(SGPT) =< . x institutional ULN -OR- AST(SGOT)/ALT(SGPT)\t=<  x institutional ULN if liver metastases are present
AST (SGOT)/ ALT (SGPT): ? . x institutional ULN
AST(SGOT)/ALT(SGPT) for patients with documented liver metastases, =<  x institutional ULN
AST (SGOT)/ALT (SGPT) ? X ULN; ?  X ULN if there is liver involvement secondary to tumor
AST (SGOT) and ALT (SGPT) ? . x ULN.
AST/SGOT and ALT/SGPT ? . x ULN
SGPT (ALT) ?  U/L and
AST (SGOT) and ALT (SGPT) =<  x ULN in patients with documented hepatic involvement by lymphoma
AST (aspartate transaminase or SGOT)/ALT (alanine aminotransferase or SGPT) ? . x ULN and total bilirubin ? . x ULN with no evidence of cholestasis
Hepatic impairment, defined as AST (SGOT), or ALT (SGPT) >  x institutional ULN, within  days of initiation of protocol therapy or
SGOT or SGPT >  x ULN
For Part B participants: SGPT (ALT) concentration < . x institutional ULN
SGPT (ALT) ?  U/L.
RETREATMENT WITH MODIFIED T CELLS: ALT (SGPT): =<  x ULN
SGPT (ALT) and SGOT (AST) less than or equal to  x normal for age
B. Hepatic: Serum total bilirubin ?. x upper limit of normal (ULN), ALT (SGPT) and AST (SGOT) ?. x ULN.
Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ? .  upper limit of normal (ULN); if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) ?   ULN.
AST / ALT (SGPT) <. x ULN
AST(SGOT)/ALT(SGPT): ? x UNL
REGISTRATION TO TREATMENT (STEP ): AST (SGOT) and ALT (SGPT) =< . X ULN OR =<  X ULN for subjects with liver metastases, within  days prior to first dose of pembrolizumab
SGOT (AST) and SGPT (ALT) > x institutional ULN
Serum AST/SGOT and ALT/SGPT ? . x ULN.
Serum AST and ALT/SGPT ? . x ULN.
AST(SGOT) and ALT(SGPT) <. x ULN
REGISTRATION # - PRIOR TO CONSOLIDATION CHEMOTHERAPY: SGOT (AST) or SGPT (ALT) =< . x IULN
AST (SGOT) and ALT (SGPT): ?.xULN OR ?xULN for subjects with liver metastases
AST (SGOT) and ALT (SGPT) < X institutional ULN (for subjects with hepatic metastases < X institutional ULN)
AST (SGOT) and ALT (SGPT) ? . x ULN
AST/SGOT and ALT/SGPT ?.ULN
ALT (SGPT) ? . X ULN for age
AST/SGOT and ALT/SGPT > . x ULN
AST (SGOT) and ALT (SGPT) ? . X ULN OR ?  X ULN for patients with liver metastases
Hepatic: Serum total bilirubin ?. x upper limit of normal (ULN), ALT (SGPT) and AST (SGOT) ?. x ULN.
AST (SGOT) and ALT (SGPT) ? . x ULN); if liver metastases are present, then ?  x ULN is allowed
SGOT and SGPT >=  x ULN; liver biopsy preferred for such patients
Obtained within  weeks from study entry: SGOT, SGPT =<  X ULN if liver metastasis present
The patient has serum total bilirubin <  g/dL (unless the patient has a diagnosis of Gilbert's disease), SGOT (ALT) <.ULN, and SGPT (AST) <.ULN
AST (SGOT) and ALT (SGPT) < =  x ULN.
AST (SGOT), ALT (SGPT) ?   ULN is allowed:
ALT (SGPT) ?   the ULN;
AST(SGOT)/ALT(SGPT) =< . X institutional ULN
AST/ALT (SGOT/SGPT) < . x ULN for the reference laboratory or <  x --ULN in the presence of liver metastases
SELUMETINIB ARM: AST/SGOT or ALT/SGPT > . x ULN (>=  ULN in presence of liver metastases)
AST/SGOT and/or ALT/SGPT > . x ULN, (>  x ULN if liver metastases present)
Serum total bilirubin ? . x ULN and AST/SGOT and ALT/SGPT ? . x ULN or ?  x ULN if liver metastases are present.
Total bilirubin ? ULN, SGOT (AST) and SGPT (ALT)< . x ULN. AST and/or ALT may be up to X ULN if with known liver metastases provided bilirubin is normal.
AST(SGOT)/ALT(SGPT) <. X institutional ULN unless due to disease
SGPT (ALT) ?  U/L and SGOT (AST) ? X ULN. (for the purpose of this study, the upper limit of normal [ULN] for SGPT [ALT] is  U/L).
Hepatic function: Serum total bilirubin ? . x ULN (upper limit of normal); AST (SGOT) and ALT (SGPT) ?  x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ?  x ULN
AST (SGOT) and ALT (SGPT) ? . x ULN. For subjects with documented liver metastases, ALT and AST ?   ULN
AST/SGOT, ALT/SGPT ?. x ULN, unless liver metastases are clearly present, then ?. x ULN
AST(SGOT)/ALT(SGPT) ? X ULN (including patients with liver metastases)
SGOT(AST) and SGPT(ALT) ?  x ULN i.e. equivalent to ? Grade  NCI-CTCAE v..
